2025-04-20-艾昆纬-降低医疗技术行业的风险和中断-加拿大IQVIA医疗技术公司应对贸易不确定性的视角（英）_17页_1mb

Summary of "Mitigating Risk and Disruption in the MedTech Sector"

Core Content

This white paper from IQVIA MedTech Canada provides an in-depth analysis of the potential impacts of new tariffs on the MedTech sector, with a specific focus on Canada and the United States. It outlines strategies for MedTech manufacturers to manage these risks and adapt to a rapidly changing global trade environment.

Main Points and Key Information

Overview of the MedTech Sector Challenges

• The MedTech sector is experiencing increased risk and disruption due to global trade tensions, including the imposition of tariffs by the U.S. and retaliatory measures by Canada and other countries.
• The U.S. has introduced a 25% additional tariff on imports from Canada and Mexico, with a 10% baseline tariff on all goods. China faces even higher tariffs, reaching 104% in total.
• These tariffs threaten to increase costs, disrupt supply chains, and reduce the competitiveness of MedTech products in both domestic and international markets.

Impact on the Canadian MedTech Market

• Canada's medical devices market was valued at $9.47 billion in 2022, accounting for 2.3% of the global market.
• In 2022, 40% of Canada’s medical technology imports came from the U.S., while China and Mexico were also major sources.
• The U.S. is the largest export market for Canada, accounting for 74% of total medical device exports.
• High-risk medical devices such as Class 3 and 4, including implants, surgical instruments, and diagnostic imaging equipment, are particularly vulnerable to tariff impacts.
• Digital health and connected devices, which are critical for personalized medicine and remote monitoring, face potential supply chain disruptions due to tariffs on IT components and semiconductors.

Impact on U.S. and Canadian MedTech Manufacturers

• U.S. manufacturers may face increased costs from tariffs on imports from China, Mexico, and Canada, and may be forced to shift production or sourcing.
• Canadian manufacturers may absorb increased costs or pass them on to consumers, risking their competitiveness in the U.S. market.
• Both countries may need to explore alternative markets and diversify supply chains to mitigate the effects of trade restrictions.

Strategies for Navigating Disruption

Short- to Medium-Term Strategies

• Market Insights and Competitive Intelligence: Gain insights from stakeholders and use data to inform decision-making.
• Advocacy and Awareness: Proactively engage with stakeholders and support educational initiatives to address tariff implications.
• Supply Chain Diversification: Identify U.S.-dependent suppliers and evaluate domestic and international alternatives.
• Localization of Production: Consider shifting production to different countries of origin to reduce tariff exposure.
• Financial and Pricing Adjustments: Simulate cost impacts, optimize pricing strategies, and explore government support programs.
• Regulatory and Trade Compliance: Prepare for regulatory changes, including duty drawback provisions and transfer pricing adjustments.
• Market and Customer Strategy Adjustments: Evaluate alternative markets, analyze legal obligations, and develop value-added services to differentiate from competitors.

Medium- to Long-Term Strategies

• Strategic Partnerships and Market Expansion: Form alliances, explore joint ventures, and expand into new markets to reduce reliance on the U.S.
• Reshoring and Nearshoring: Consider reshoring to Mexico and Canada as part of 'friendshoring' strategies.
• Investment in Domestic Manufacturing: Develop local manufacturing capabilities to bypass tariffs and improve supply chain resilience.
• Financial Diversification: Build long-term revenue streams and secure financial support through grants and tax incentives.
• Innovation and Digital Transformation: Invest in smart manufacturing, automation, and data-driven decision-making to enhance agility and competitiveness.

Key Recommendations

• MedTech companies should be proactive in addressing trade uncertainties.
• Scenario and sensitivity analyses should be conducted to prepare for various tariff outcomes.
• Supply chain diversification, regulatory agility, and financial planning are critical for long-term resilience.
• Collaboration with industry associations and leveraging data-driven tools can help companies adapt effectively.

Conclusion

The Canadian MedTech industry is at a crossroads due to trade uncertainties and evolving regulatory environments. While these challenges pose risks, they also present opportunities for innovation, diversification, and resilience. By implementing both short- and long-term strategies, MedTech companies can navigate the current landscape and position themselves for future growth.

IQVIA MedTech offers a data-driven approach to help companies manage these uncertainties through comprehensive trade and market intelligence, competitive and regulatory insights, and supply chain and financial analysis.